|
内容記述 |
Uterine serous carcinoma (USC) is a rare aggressive type 2 endometrial carcinoma with dismal prognosis. Peritoneal metastasis (PM) is often observed even at early stage in USC. HER2 is a therapeutic target of USC and trastuzumab, the anti-HER2 antibody, has shown benefit in the treatment of HER2 positive USC. However, the acquired resistance of trastuzumab also has been challenges to overcome for HER2 positive USC. Targeted alpha therapy (TAT) is useful not only for local tumor but also metastasis. Having the target specificity of antibody and high cell cytotoxicity and short range of alpha-particle, TAT can effectively control targeted tumor with minimal toxicity to untargeted normal tissues. Astatine 211 (<SUP>211</SUP> At) is one of the attractive alpha-emitter. We have performed experimental TAT using <SUP>211</SUP>At-trastuzumab to preclinical mouse model with trastuzumab resistant PM of HER2 positive USC in order to investigate the therapeutic efficacy and toxicity. We will discuss the potential of TAT as a novel therapeutic option for drug resistant PM of HER2 positive USC. |
